Endocrine Testing Market Size & Share 2025 – 2034

Endocrine Testing Market Size

The global endocrine testing market size was valued at USD 3.1 billion in 2024 and is expected to exhibit growth at a CAGR of 8.2% from 2025 to 2034 period. The market growth is attributed to the rising prevalence of endocrine disorders, supportive government funding initiatives, growing awareness of routine health monitoring, contributing to their growing adoption.   
 

Conditions like diabetes and thyroid dysfunction are among the most common endocrine disorders globally. According to the Centers for Disease Control and Prevention (CDC), as of 2022, approximately 37.3 million people in the U.S. had diabetes, further emphasizing the growing need for endocrine tests. Similarly, thyroid disorders, including hypothyroidism and hyperthyroidism, require routine thyroid function testing to monitor hormone levels and guide treatment.
 

Endocrine testing refers to a range of diagnostic procedures and laboratory analyses designed to assess the functioning of the endocrine system, which regulates hormonal balance in the body. This testing involves the measurement of hormone levels, metabolites, or glandular function to diagnose and monitor conditions such as thyroid disorders, diabetes, adrenal insufficiency, growth abnormalities, and reproductive health issues.
 

Endocrine Testing Market Trends

The introduction of technologies such as mass spectrometry and chemiluminescent immunoassays has significantly improved the precision of endocrine testing.
 

• Automation in diagnostic laboratories has streamlined endocrine testing processes, reducing manual errors and increasing throughput. Automated analyzers equipped with robotic arms and integrated data management systems facilitate rapid and reliable results, catering to the growing demand for endocrine diagnostics.
   
• Additionally, the development of portable, user-friendly endocrine testing devices has brought diagnostics closer to patients. Point-of-care testing solutions for conditions such as diabetes and thyroid disorders allow immediate results and improved convenience, particularly in remote and underserved areas.
   
• Furthermore, artificial intelligence (AI) and machine learning algorithms are increasingly used to analyze endocrine testing data, providing predictive insights and enhancing diagnostic accuracy. Digital health platforms also enable seamless integration of test results into electronic health record (EHR), ensuring better communication between healthcare providers and patients.
   

Endocrine Testing Market Analysis

Based on test type, the market is segmented as human chorionic gonadotropin (hCG) hormone test, thyroid stimulating hormone (TSH) test, insulin test, progesterone test, luteinizing hormone (LH) test, prolactin test, and other test types. The human chorionic gonadotropin (hCG) hormone test segment is expected to drive business growth and expand at a CAGR of 7.6%, reaching over USD 2 billion by 2034.
 

• The hCG hormone test is widely used for confirming pregnancy, as it detects the presence of the hormone produced shortly after fertilization. The reliability and ease of use of modern pregnancy test kits have made hCG testing a staple in both clinical and home settings, driving consistent demand.
   
• Additionally, beyond pregnancy detection, hCG tests are crucial in assessing fertility treatments, monitoring ovulation, and diagnosing reproductive health disorders. The increasing prevalence of infertility, coupled with advancements in assisted reproductive technologies (ART), has amplified the demand for hCG hormone testing.
   

Based on technology, the endocrine testing market is segmented as immunoassay, mass spectroscopy, chromatography, nucleic acid based, and other technologies. The immunoassay segment dominated the market in 2024 with a market share of 40.1%.
 

• Immunoassays are renowned for their ability to detect hormones and biomarkers at extremely low concentrations, making them invaluable for diagnosing endocrine disorders such as hypothyroidism, diabetes, and reproductive hormone imbalances. Their precision ensures accurate test results, which are crucial for effective patient management.
   
• Additionally, compared to advanced technologies like mass spectrometry, immunoassays are more cost-effective, making them accessible to a broader range of healthcare facilities. This affordability contributes to their widespread adoption, particularly in regions with limited healthcare budgets.
   

Based on end use, the endocrine testing market is segmented as hospitals, clinical laboratories, diagnostic centers, and other end users. The clinical laboratories segment dominated the market in 2024 and is anticipated to reach USD 3.4 billion by the end of the forecast period.
 

• Clinical laboratories are equipped with state-of-the-art technologies and staffed by skilled professionals, enabling them to perform complex endocrine tests, including hormone assays and biomarker analysis. This specialization makes them a trusted choice for accurate and reliable diagnostics, particularly for conditions like diabetes, thyroid dysfunction, and adrenal disorders.
   
• The scalability of clinical laboratories allows them to handle large volumes of tests efficiently. Their centralized operations ensure standardized procedures, minimizing errors and improving turnaround times, which is critical in endocrine testing where timely results are essential for effective treatment.
   

The U.S. endocrine testing market accounted for USD 1.2 billion in 2024 and is anticipated to grow at a CAGR of 7.2% between 2025 to 2034 period.
 

• The presence of leading diagnostic companies and laboratories ensures the availability of cutting-edge testing solutions.
   
• Government initiatives to address chronic diseases and promote preventive healthcare further drive demand.
  
   
• Additionally, the growing adoption of point-of-care testing and personalized medicine has boosted the market growth in the U.S.
   

France endocrine testing market is projected to grow remarkably in the coming years.
 

• The country has a well-established network of laboratories equipped with modern diagnostic technologies such as mass spectrometry and chemiluminescent immunoassays.
   
• A strong focus on public health campaigns to raise awareness about endocrine disorders, combined with government-supported healthcare programs, fuels the demand for diagnostic tests. France leadership in innovation and research further bolsters its share in the market.
   

Japan holds a dominant position in the Asia Pacific endocrine testing market.
 

• The country is a leader in adopting cutting-edge diagnostic technologies, including automation and multiplex testing platforms.
   
• Japan’s focus on preventive care and early disease detection, supported by government initiatives, drives market growth.
   
• Additionally, the integration of diagnostics with digital health solutions and telemedicine enhances accessibility and efficiency, further strengthening its market position.
   

Endocrine Testing Market Share

Several key players in the market are making strides in type innovation and strategic partnerships to maintain market leadership. Companies are investing heavily in R&D to develop advanced endocrine testing with enhanced features such as the integration of advanced testing platforms, automation in laboratories, and the emergence of multiplex testing.
 

Additionally, partnerships with healthcare providers are being forged to improve type accessibility in emerging markets. Regulatory compliance and adherence to international quality standards are crucial aspects of the strategies employed by these companies to cater to a global market. These developments are helping companies meet the increasing demand for safe and efficient endocrine testing devices.
 

Endocrine Testing Market Companies

Prominent players operating in the endocrine testing industry include:

• Abbott
• Agilent
• BECKMAN COULTER
• BIO RAD
• biomedical TECHNOLOGIES
• BIOMERIEUX
• DH TECH
• Diasorin
• labcorp
• QuidelOrtho
• QIAGEN
• Quest Diagnostics
• Roche
• SCIEX
• SIEMENS Healthineers
• Thermo Fisher SCIENTIFIC
   

Endocrine Testing Industry News:

• In January 2024, Agilent Technologies announced the launch of its new PathHunter Testing System, designed to enhance the accuracy and efficiency of endocrine disorder diagnostics. This innovative system integrates advanced chemiluminescent technology with high-throughput capabilities, enabling precise measurement of hormone levels in various biological samples.
   

The endocrine testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Market, By Test Type

• Human chorionic gonadotropin (hCG) hormone test
• Thyroid stimulating hormone (TSH) test
• Insulin test
• Progesterone test
• Luteinizing hormone (LH) test
• Prolactin test
• Other test types

Market, By Technology

• Immunoassay
• Mass spectroscopy
• Chromatography
• Nucleic acid based
• Other technologies

Market, By End Use

• Clinical laboratories
• Hospitals
• Diagnostic centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE